Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2020-07, Vol.136 (1), p.137-139
Hauptverfasser:	Frigault, Matthew J., Nikiforow, Sarah, Mansour, Michael K., Hu, Zhen-Huan, Horowitz, Mary M., Riches, Marcie L., Hematti, Peiman, Turtle, Cameron J., Zhang, Mei-Jie, Perales, Miguel-Angel, Pasquini, Marcelo C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Betacoronavirus - drug effects Coronavirus Infections - etiology COVID-19 Cytokine Release Syndrome - complications Cytokine Release Syndrome - drug therapy Female Hematologic Neoplasms - complications Hematologic Neoplasms - therapy Humans Immunotherapy, Adoptive - adverse effects Letters to Blood Male Middle Aged Pandemics Pneumonia, Viral - etiology Risk Factors SARS-CoV-2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!